Inventiva SA (IVA) PT Lowered to $11 at Guggenheim

Guggenheim analyst Etzer Darout lowered the price target on Inventiva SA (NASDAQ: IVA) to $11.00 (from $13.00) while maintaining a Buy rating.

The analyst commented: "We are updating our model to incorporate IVA's announcement of $172.5M (or €149.0M) in equity financing, which the co. plans to use to fund continuation of the NATiV3 Phase 3 trial, in preparation and initiation of the outcome trial, and for commercialization activities. Our risk-adjusted PT moves to $11/share (from $13/share), or $4.4B on a fully diluted basis, and we reiterate our BUY rating ahead of the high PoS pivotal NATiV3 Phase 3 results approaching in 2H26 for what we believe can be a best in-class oral antifibrotic MASH treatment to compete with MDGL’s resmetirom."

You May Also Be Interested In

• Travel + Leisure (TNL) PT Raised to $91 at Stifel
• ASM International posts Q3 net income of €308.1m, raises 2027 revenue target
• Raymond James on Lakeland Financial (LKFN): 'We expect solid growth momentum to continue'